This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (NURTURE)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Biogen Identifier:
First received: February 27, 2015
Last updated: August 15, 2017
Last verified: August 2017
The primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA). Secondary objectives of this study are to examine the effects of Nusinersen in infants with genetically diagnosed and presymptomatic SMA.

Condition Intervention Phase
Spinal Muscular Atrophy Drug: Nusinersen Phase 2

Access to an investigational treatment associated with this study is available outside the clinical trial.   More info ...

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.

Resource links provided by NLM:

Further study details as provided by Biogen:

Primary Outcome Measures:
  • Time to death or respiratory intervention [ Time Frame: Up to Day 1820 ]
    The time will be the age of the participant at the first occurrence of either a respiratory intervention or death. Respiratory intervention is defined as invasive or noninvasive ventilation for ≥6 hours/day continuously for 7 or more days OR tracheostomy.

Secondary Outcome Measures:
  • Percentage of participants developing clinically manifested spinal muscular atrophy (SMA). [ Time Frame: At 13 and 24 months of age ]
  • Percentage of participants alive [ Time Frame: At 13 months, and 2, 3, 4 and 5 years of age ]
  • Percentage of participants who attained motor milestones assessed as part of the Hammersmith Infant Neurological Examination (HINE) [ Time Frame: At 13 and 24 months of age ]
  • Percentage of participants who attained motor milestones as assessed by World Health Organization (WHO) criteria [ Time Frame: At 13 and 24 months of age ]
  • Change from Baseline in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function scale [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in weight for age/length [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in head circumference [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in chest circumference ratio [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in head to chest circumference ratio [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in arm circumference ratio [ Time Frame: Up to Day 1820 ]
  • Incidence of adverse events (AEs) and/or serious adverse events (SAEs) [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in clinical laboratory parameters [ Time Frame: Up to Day 1820 ]
    Assessed by the following laboratory tests: Hematology: red blood cells, hemoglobin, hematocrit, platelets, white blood cells, white blood cell differential, Blood chemistry: total protein, albumin, creatinine, cystatin C, creatine phosphokinase, blood urea nitrogen, total bilirubin (direct and indirect), alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, glucose, calcium, phosphorous, chloride, sodium, potassium. Urinalysis: specific gravity, pH, protein, glucose, ketones, bilirubin, red blood cells, white blood cells, epithelial cells, bacteria, casts, crystals

  • Change from Baseline in electrocardiograms (ECGs) [ Time Frame: Up to Day 1820 ]
  • Change from Baseline in vital signs [ Time Frame: Up to Day 1820 ]
    Vital sign will be assessed by: temperature, pulse rate, resting systolic and diastolic blood pressure, and respiratory rate.

  • Change from Baseline in neurological examinations [ Time Frame: Up to Day 1820 ]
  • Cerebrospinal fluid (CSF) and plasma Nusinersen concentrations. [ Time Frame: Up to Day 1730 ]

Enrollment: 25
Actual Study Start Date: May 20, 2015
Estimated Study Completion Date: January 26, 2022
Estimated Primary Completion Date: January 26, 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nusinersen
Nusinersen administered as an intrathecal injection
Drug: Nusinersen
Solution for intrathecal injection
Other Names:
  • ISIS 396443
  • BIIB058
  • Spinraza


Ages Eligible for Study:   up to 6 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Age ≤ 6 weeks at first dose
  • Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound heterozygous mutation.
  • Genetic documentation of 2 or 3 copies of survival motor neuron 2 (SMN2).
  • Ulnar compound muscle action potential (CMAP) ≥ 1 mV at Baseline.
  • Gestational age of 37 to 42 weeks for singleton births; gestational age of 34 to 42 weeks for twins.
  • Meet additional study related criteria.

Key Exclusion Criteria:

  • Hypoxemia (oxygen saturation <96% awake or asleep without any supplemental oxygen or respiratory support).
  • Any clinical signs or symptoms at Screening or immediately prior to the first dosing (Day 1) that are, in the opinion of the Investigator, strongly suggestive of SMA.
  • Clinically significant abnormalities in hematology or clinical chemistry parameters.
  • Treatment with an investigational drug given for the treatment of SMA biological agent, or device. Any history of gene therapy, prior antisense oligonucleotide (ASO) treatment, or cell transplantation.
  • Meet additional study related criteria.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02386553

United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Florida
Nemours Children's Clinic
Orlando, Florida, United States, 32827
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Maryland
The Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, New York
Columbia University Medical Center, The SMA Clinical Research Center
New York, New York, United States, 10032
United States, Utah
Primary Children's Medical Center
Salt Lake City, Utah, United States, 84112
Australia, Victoria
Royal Children's Hospital- Melbourne
Parkville, Victoria, Australia, 3052
Dept. of Neuropediatrics and Muscle Disorders Universitätsklinikum Freiburg
Freiburg, Baden-Württemberg, Germany, 79106
Bambino Gesu' Children's Research Hospital
Roma, Lazio, Italy, 165
Fondazione Serena Onlus - Centro Clinico Nemo
Milano, Italy, 20162
Hamad General Hospital
Doha, Qatar, 3050
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 806
National Taiwan University Hospital
Taipei, Taiwan, 100
Hacettepe University Medical Faculty
Ankara, Sihhiye, Turkey, 6100
Sponsors and Collaborators
Study Director: Medical Director Biogen
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Biogen Identifier: NCT02386553     History of Changes
Other Study ID Numbers: 232SM201
2014-002098-12 ( EudraCT Number )
Study First Received: February 27, 2015
Last Updated: August 15, 2017

Keywords provided by Biogen:

Additional relevant MeSH terms:
Muscular Atrophy
Muscular Atrophy, Spinal
Pathological Conditions, Anatomical
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Spinal Cord Diseases
Central Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
Neuromuscular Diseases processed this record on September 20, 2017